Log In
Print this Print this

Kerydin, tavaborole (formerly AN2690)

  Manage Alerts
Collapse Summary General Information
Company Anacor Pharmaceuticals Inc.
DescriptionTopical oxaborole antifungal agent
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationOnychomycosis
Indication DetailsTreat onychomycosis
Regulatory Designation U.S. - Special Protocol Assessment (Treat onychomycosis);
U.S. - Undisclosed Review (Treat onychomycosis)
Partner Novartis AG

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today